<SEC-DOCUMENT>0001193125-19-272683.txt : 20191023
<SEC-HEADER>0001193125-19-272683.hdr.sgml : 20191023
<ACCEPTANCE-DATETIME>20191023171610
ACCESSION NUMBER:		0001193125-19-272683
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20191023
DATE AS OF CHANGE:		20191023

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-226452
		FILM NUMBER:		191164404

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d836031dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Issuer Free Writing Prospectus dated October&nbsp;23, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Relating to Preliminary Prospectus Supplement dated October&nbsp;23, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 433 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-226452</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g836031g66h92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOCA RATON, Fla, October</B><B></B><B>&nbsp;23, 2019 &#150; </B>TherapeuticsMD, Inc.&nbsp;(NASDAQ:TXMD) (the &#147;Company&#148;) today announced its
estimates of the financial results for the third quarter ended September&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended September&nbsp;30, 2019, the Company
estimates that its consolidated net revenue from its prescription vitamin business will range from approximately $2.50&nbsp;million to $2.60&nbsp;million, compared to consolidated net revenue from its prescription vitamin business of approximately
$2.80&nbsp;million for the three months ended June&nbsp;30, 2019. For the three months ended September&nbsp;30, 2019, the Company estimates that its consolidated net revenue from sales of its U.S. Food and Drug Administration approved products
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, BIJUVA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and ANNOVERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> will range from approximately
$5.32&nbsp;million to $5.70&nbsp;million, compared to consolidated net revenue from sales of IMVEXXY and BIJUVA of approximately $3.3&nbsp;million for the three months ended June&nbsp;30, 2019. Sales of ANNOVERA commenced in August 2019. The Company
estimates that its consolidated net revenue by product for the three months ended September&nbsp;30, 2019 will be as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IMVEXXY consolidated net revenue for the three months ended September&nbsp;30, 2019 will range from approximately
$4.5&nbsp;million to $4.8&nbsp;million, compared to approximately $3.1&nbsp;million for the three months ended June&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BIJUVA consolidated net revenue for the three months ended September&nbsp;30, 2019 will range from approximately
$450,000 to $500,000, compared to approximately $134,000 for the three months ended June&nbsp;30, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ANNOVERA consolidated net revenue for the three months ended September&nbsp;30, 2019 will range from
approximately $375,000 to $400,000. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates that, as of September&nbsp;30, 2019, it had approximately $155.3&nbsp;million
of cash and cash equivalents. As a result of the Company&#146;s commercial sales of ANNOVERA, as of September&nbsp;30, 2019, the Company had accrued a current liability of $20&nbsp;million representing the milestone payment due to the Population
Council under the Company&#146;s license agreement for ANNOVERA. The Company expects to pay this milestone in the fourth quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing
amounts are unaudited and preliminary, and do not present all information necessary for an understanding of the Company&#146;s financial condition as of September&nbsp;30, 2019. The review of the Company&#146;s consolidated financial statements for
the three months ended September&nbsp;30, 2019 is ongoing and could result in changes to these amounts due to the completion of financial closing procedures, final adjustments and other developments that may arise between now and the time the
consolidated financial statements for the three months ended September&nbsp;30, 2019 are finalized and publicly released. The Company&#146;s independent registered public accounting firm, Grant Thornton LLP, has not audited, reviewed, or compiled
these estimates. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD has filed a registration statement (including a prospectus) with the SEC for the offering to
which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get
these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-803-9204.</FONT></FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
TherapeuticsMD, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc.&nbsp;is an innovative, leading healthcare company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The
company is committed to advancing the health of women and championing awareness of their healthcare issues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to,
statements relating to TherapeuticsMD&#146;s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often characterized by terminology such as &#147;believes,&#148; &#147;hopes,&#148; &#147;may,&#148; &#147;anticipates,&#148; &#147;should,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;will,&#148; &#147;expects,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;positioned,&#148; &#147;strategy&#148; and similar expressions and are based on assumptions and assessments made in light of management&#146;s experience and
perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company
undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of
which are outside of the company&#146;s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled &#147;Risk
Factors&#148; in the company&#146;s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and include the following: the company&#146;s ability to maintain or increase sales of its products; the company&#146;s ability to
develop and commercialize IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, ANNOVERA<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, BIJUVA<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and its hormone therapy drug
candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could
adversely affect the commercialization of the company&#146;s current or future approved products or preclude the approval of the company&#146;s future drug candidates; the length, cost and uncertain results of future clinical trials; the
company&#146;s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company&#146;s licensees to commercialize and distribute the company&#146;s products; the availability of
reimbursement from government authorities and health insurance companies for the company&#146;s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of
the company&#146;s common stock and the concentration of power in its stock ownership. PDF copies of the company&#146;s historical press releases and financial tables can be viewed and downloaded at its website:
<U>www.therapeuticsmd.com/pressreleases.aspx</U>. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I># # # </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nichol Ochsner </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">561-961-1900</FONT></FONT> Ext. 2088 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>nochsner@TherapeuticsMD.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g836031g66h92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g836031g66h92.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M7.>R)0(\Z^-'_(H67_7^G_HN2NS!_&_0X<?_  UZ_P"9VOA__D6]+_Z](O\
MT 5S5/C9UTO@CZ'G7Q'B2;XB^$8I4#QO-&K*>A!E&179A]*4_P"NAPXI7K03
M_K4]5]JX#TCQKX?F2UT[Q\MF-KPQGR5'8@38Q^0KT:^KIW_K8\G#74:MOZW*
M'P]O/&5GHD__  C6BV-W;O.?,EF<!]P ^7_6+P![=S5UU2<O?;7]>A&&E6C%
M^SBG_7J:/BC3/B+XML8;34/#=DBQ2>8CPRH&'!&,F0\'/Z"HI2H4G=2_K[BZ
MT,365I17]?,3XJ6MQ+9^#K2Y.VZ9'CD).</B('D>]&%:3FU_6X8R+:II[_\
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MLOF;/Q'_ .8'_P!?@_I6-#J89I_R[]37\7^'1K^E?N/DO[<[[=\X.?[N??\
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MT6ST'3DLK-"$'+,W+.WJ:QE)R=V>E0P\,/#D@:-2= 4 % !0 4 % !0 4 %
M!0 4 % !0!@:SX0T_7-<TW5KF:X2XT]U>)8V4*2&##=D$]1V(K6%64(N*ZF$
MZ$9S4WT-^LC<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
# __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
